<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MYC deregulation is common in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>IG-MYC translocations that are modeled in Eμ-Myc mice occur in almost <z:hpo ids='HP_0000001'>all</z:hpo> cases of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> as well as in other B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Deregulated expression of MYC results in increased mTOR complex 1 (mTORC1) signaling </plain></SENT>
<SENT sid="3" pm="."><plain>As <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with mTORC1 activation are sensitive to mTORC1 inhibition, we used everolimus, a potent and specific mTORC1 inhibitor, to test the requirement for mTORC1 in the initiation and maintenance of Eμ-Myc <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Everolimus selectively cleared premalignant B cells from the bone marrow and spleen, restored a <z:mpath ids='MPATH_458'>normal</z:mpath> pattern of B-cell differentiation, and strongly protected against <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development </plain></SENT>
<SENT sid="5" pm="."><plain>Established Eμ-Myc <z:hpo ids='HP_0002665'>lymphoma</z:hpo> also regressed after everolimus therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Therapeutic response correlated with a cellular senescence phenotype and induction of p53 activity </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, mTORC1-dependent evasion of senescence is critical for cellular transformation and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> maintenance by MYC in B lymphocytes </plain></SENT>
<SENT sid="8" pm="."><plain>SIGNIFICANCE: This work provides novel insights into the requirements for MYC-induced <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> by showing that mTORC1 activity is necessary to bypass senescence during transformation of B lymphocytes </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> eradication through senescence elicited by targeted inhibition of mTORC1 identifies a previously uncharacterized mechanism responsible for significant anticancer activity of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> analogues and serves as proof-of-concept that senescence can be harnessed for therapeutic benefit </plain></SENT>
</text></document>